EC Number   |
Application |
Reference |
|---|
    1.13.11.27 | drug development |
plant 4-hydroxyphenylpyruvate dioxygenase (HPPD) is the molecular target for development of specific inhibitors |
741741 |
| 1.13.11.27 | drug development |
the enzyme is a target for inhibitor and herbicide development |
741762 |
| 1.13.11.27 | drug development |
the enzyme is an important target for treating type I tyrosinemia and alkaptonuria due to its significant role in tyrosine catabolism |
742068 |
| 1.13.11.27 | drug development |
the human enzyme is a target for drug development in treatment of type 1 tyrosinemia, alkaptonuria, and hawkinsinuria, overvuew |
741762 |
| 1.13.11.27 | environmental protection |
the enzyme can be used for enzyme-based sensors for monitoring herbicides used in agriculture, i.e. mesotrione. Compared to the standard sensors, biosensors have assorted advantages, such as practicality, quick response, low cost, and high sensitivity. A nanobiosensor is developed based on HPPD for mesotrione detection |
742632 |
| 1.13.11.27 | medicine |
4-hydroxyphenylpyruvate dioxygenase (HPPD), an essential enzyme in tyrosine catabolism, is an important target for treating type I tyrosinemia |
742451 |
| 1.13.11.27 | medicine |
compounds N-(4-methoxyphenyl)-7-nitro-2,1,3-benzoxadiazol-4-amine and 3-(2-bromo-4-methylphenyl)-6-(5-hydroxy-1-methyl-1H-pyrazole-4-carbonyl)-2-methylquinazolin-4(3H)-one can be potentially useful for the treatment of type I tyrosinemia and other diseases with defects in tyrosine degradation |
742068 |
| 1.13.11.27 | medicine |
HPD is highly expressed in lung cancer and expression correlates with poor prognosis in lung cancer patients. Suppressed HPD expression is sufficient to decrease oxidative pentose phosphate pathway flux, leading to reduced RNA biosynthesis and enhanced reactive oxygen species level, attenuated cancer cell proliferation, and tumor growth |
764434 |
| 1.13.11.27 | medicine |
mechanism of binding of the inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione used to treat type I tyrosinemia. Enzyme-Fe(II)-inhibitor complex does not oxidize, dissociation rate constant is essentially zero |
657941 |
| 1.13.11.27 | synthesis |
overexpression of the HppD gene in Escherichia coli to produce large amounts of pyomelanin for biotechnological purposes. The recombinant dioxygenase expression leads to the production of pyomelanin in Escherichia coli. When cells are grown at the mid-exponential phase in a mineral medium with added glucose 10 mM and casamino acid 0.2 % w/v, the administration of tyrosine 1 mM after 30 minutes of exposure to arabinose 1 % w/v allows to purify 213 mg/l of pyomelanin after 6 days of biotransformation |
764873 |
